A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Impact of mammographic screening on the detection of good and poor prognosis breast cancers

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Quality of Life Differences between Younger and Older Breast Cancer Patients

(2011) Byeong-Woo Park et al.   Journal of Breast Cancer

Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?

(2011) Philippe L. Bedard et al.   Nature Reviews Clinical Oncology

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

(2010) Valesca P. Retèl et al.   EUROPEAN JOURNAL OF CANCER

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age

(2009) S. Mook et al.   ANNALS OF ONCOLOGY

Validation of 70-gene prognosis signature in node-negative breast cancer

(2008) J. M. Bueno-de-Mesquita et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

(2008)   LANCET

Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer

(2008) J. S. Ross et al.   ONCOLOGIST